The bill seeks to accelerate access to and clarity around OTC sunscreen ingredients, increase transparency, and reduce animal testing—trade‑offs include higher costs, added regulatory workload, and potential safety or availability risks from alternative approval pathways.
People at risk of skin cancer (children, young adults, seniors, chronic patients) and the general public would gain stronger prevention guidance, clearer FDA standards, and improved access to proven sun protection, reducing long-term skin cancer risk.
Consumers (including children and patients) could get faster access to potentially safer or more effective sunscreen active ingredients because the bill allows real‑world evidence and clarifies alternative approval pathways.
Manufacturers, researchers, and consumers would benefit from greater regulatory certainty and transparency—codified evidence standards, required consideration of historical data, and public progress reports make approval expectations clearer.
Taxpayers and manufacturers could face higher costs from new regulatory guidance, reporting requirements, testing evaluations, and potential reformulation or compliance work.
Allowing looser evidentiary pathways (real‑world/observational studies) and expedited/alternative approvals could create uncertainty about long‑term safety, increasing risk that some products may be ineffective or harmful for vulnerable users.
More prescriptive or stricter testing standards in some respects could paradoxically delay approval of certain OTC sunscreen ingredients, reducing short‑term product availability for consumers (especially seniors).
Based on analysis of 5 sections of legislative text.
Requires FDA to modernize sunscreen active ingredient evaluation by accepting non-animal tests and real-world evidence and issuing guidance within 180 days.
Directs the FDA to modernize how it evaluates sunscreen active ingredients by establishing updated safety and effectiveness standards, formally accepting non-animal testing alternatives, and permitting real-world evidence and observational studies in place of or alongside traditional clinical testing. Requires FDA to issue guidance within 180 days, to fold the new standards into the pending OTC sunscreen active ingredient administrative order, and to report annually to Congress on implementation and use of nonclinical alternative tests.
Introduced June 3, 2025 by John Joyce · Last progress June 3, 2025